Acquired by New Relic.
ABSCINT is developing single-domain antibodies for disease diagnosis through imaging.
Flindr aims to restore a patient’s impaired immune response to cancer
Aloxy’s Internet of Things technology is enabling the petrochemical industry to innovate.
